Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

MVMR results of fibroblast growth factor 23 on the risk of abdominal aortic calcification. Exposure | Outcome | Adjustment | Beta | OR (95% CI) | P value: Serum 25-hydroxyvitamin D levels | 0.087 | 1.091 (1.028 to 1.157) | .004

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

For this secondary analysis, SNPs associated with FGF23 were selected using a relaxed significance threshold of P < 1 × 10−6, reflecting the limited number of genome-wide significant variants available.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

FGF-23 is associated with increased risk of abdominal aortic calcification

Secondary analysis · Medicine · 2026

Original publication title

FGF-23 is associated with increased risk of abdominal aortic calcification

Lei Song; Juan Chen; Cheng Xue; Chang Song; Jinhua Zhu; Daoliang Xu

Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Fibroblast growth factor 23 (FGF23) is involved in the regulation of phosphate metabolism and has been linked to vascular calcification. However, the genetic association between FGF23 and abdominal aortic calcification (AAC) remains unclear. We conducted a bidirectional two-sample Mendelian randomization (MR) study to evaluate the association between genetically predicted circulating FGF23 levels and AAC. Univariable MR was performed to assess the primary association, followed by multivariable MR adjusting for serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and chronic kidney disease. In addition, a two-step MR mediation analysis was used to assess whether phosphate might mediate this association.

Univariable MR analysis suggested a modest association between genetically predicted circulating FGF23 levels and a higher risk of AAC (odds ratio = 1.082, 95% confidence interval = 1.016 to 1.151, P = .013). This association remained directionally consistent after separate adjustment for serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and chronic kidney disease. In a secondary multivariable Mendelian randomization analysis using an alternative FGF23 genome-wide association study, the association was no longer statistically significant after adjustment for phosphate (odds ratio = 1.064, 95% confidence interval = 0.962 to 1.179, P = .224).

Two-step MR mediation analysis suggested that serum phosphate may partially mediate the association between FGF23 and AAC, with a marginally significant indirect effect (inverse-variance weighted: β = 0.024, P = .049), accounting for approximately 30% of the total effect. Our findings provide suggestive evidence that genetically predicted higher FGF23 levels may be modestly associated with an increased risk of AAC, with serum phosphate potentially acting as a partial mediator.

Authors’ abstract

Fibroblast growth factor 23 (FGF23) is involved in the regulation of phosphate metabolism and has been linked to vascular calcification. However, the genetic association between FGF23 and abdominal aortic calcification (AAC) remains unclear. We conducted a bidirectional two-sample Mendelian randomization (MR) study to evaluate the association between genetically predicted circulating FGF23 levels and AAC. Univariable MR was performed to assess the primary association, followed by multivariable MR adjusting for serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and chronic kidney disease. In addition, a two-step MR mediation analysis was used to assess whether phosphate might mediate this association.

Univariable MR analysis suggested a modest association between genetically predicted circulating FGF23 levels and a higher risk of AAC (odds ratio = 1.082, 95% confidence interval = 1.016 to 1.151, P = .013). This association remained directionally consistent after separate adjustment for serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and chronic kidney disease. In a secondary multivariable Mendelian randomization analysis using an alternative FGF23 genome-wide association study, the association was no longer statistically significant after adjustment for phosphate (odds ratio = 1.064, 95% confidence interval = 0.962 to 1.179, P = .224).

Two-step MR mediation analysis suggested that serum phosphate may partially mediate the association between FGF23 and AAC, with a marginally significant indirect effect (inverse-variance weighted: β = 0.024, P = .049), accounting for approximately 30% of the total effect. Our findings provide suggestive evidence that genetically predicted higher FGF23 levels may be modestly associated with an increased risk of AAC, with serum phosphate potentially acting as a partial mediator.

Publication and source details

Original title: FGF-23 is associated with increased risk of abdominal aortic calcification

Lei Song; Juan Chen; Cheng Xue; Chang Song; Jinhua Zhu; Daoliang Xu

Medicine · 2026

* Correspondence: Daoliang Xu, Division of Nephrology, Subei People’s Hospital of Jiangsu Province, Medical College of Yangzhou University, 98 Nantong West Road, Yangzhou 225001, Jiangsu Province, China (e-mail: 13852990176@163.com, xdl@126.com).Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Shanghai Scientific and technological innovation action plan22Y11905500Cheng XueShanghai Scientific and technological innovation action plan24142201800Cheng Xue

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:36:39.719013+00:00

DOI: 10.1097/md.0000000000050966 · PMC13633000